Women's Health

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.

FDA tackles women's sexual health

The regulator and patients will chat for two days in October.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

NIH: HPV test beats Pap for cancer assessment

HPV testing provides an edge over Pap screenings when it comes to detecting cervical cancer risk.

ACP says no need for pelvic exams

The American College of Physicians says most women do not need an annual pelvic exam. The American College of Obstetrics and Gynecologists disagrees.

Panel votes against AZ's olaparib

Panel votes against AZ's olaparib

By

An FDA advisory panel voted 11-2 against an accelerated approval for AstraZeneca's experimental PARP inihibitor. The panel recommends getting more data before giving the drug the all-clear.

Campaigners want FDA to focus on women's sexual health

Campaigners want FDA to focus on women's sexual health

By

A coalition of organizations, including pharmaceutical company Sprout, kicked off a campaign urging the FDA to pay as much attention to women's sexual dysfunction needs as it does to men's.

KV rebrands, becomes Lumara Health

KV rebrands, becomes Lumara Health

By

The post-Chapter 11 pharmaceutical company unveiled its new name Thursday.

Bayer encourages daily calcium with a side of defiance

Its "Beauty is Bone Deep" campaign looks at beauty from the inside.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

By

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

By

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

FDA wants parents to back off fetus selfies

The regulator says at-home ultrasounds and heart monitoring systems are a bad idea.

Study shows HPV vax impact

Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.

FDA ends Teva Plan B OTC dominance

The regulator is allowing generic makers room on the OTC contraceptive shelf.

Advil hearts menstrual cramps

Advil hearts menstrual cramps

By

Pfizer's consumer website for Advil in South Korea offers a strange appeal to women who experience menstrual pain.

Merck sends HPV vax to FDA

Merck sends HPV vax to FDA

By

The drugmaker's new vaccine has more brawn, but vaccination rates among boys and girls remain low.

Panel urges increased HPV vaccination rates

Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.

Merck may be near NuvaRing settlement

The drugmaker may be able to settle around 3,800 cases for $100 million.

Birth control football remains in play

The White House has until Friday to issue a response to a Supreme Court injunction that temporarily eased birth-control coverage requirements.

Viagra population could double

A Penn State researcher thinks it can help women with menstrual cramps.

Analyst: Don't underestimate AbbVie

Analyst: Don't underestimate AbbVie

By

Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.

Pediatricians want greater condom access

The AAP says greater access and education are critical in curbing STIs.

Roche posts sales increase

Roche posts sales increase

By

Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.

Quest joins breast cancer gene-testing market

The diagnostics firm is undercutting Myriad's cost by almost $1,000.

Bayer: 5 new Phase III drugs expected in 2015

The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.

Merck reorg reimagines sales force

Merck reorg reimagines sales force

By

The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.

FDA okays Perjeta for first-line breast cancer treatment

FDA okays Perjeta for first-line breast cancer treatment

By

The second-line drug sped from Priority Review status for the first-line indication to approval in just over two months.

Breast cancer risk awareness shown lagging

By

Researchers surveying 21 Long Island mammography centers found that women do not know their risk.

Novo taps five experts for their brash take on menopause

Novo taps five experts for their brash take on menopause

By

The drug maker brought together a group of five established healthcare advocates under the umbrella GLAM, short for Great Life After Menopause. The advocates will keep their distinct voices, which are anything but muted.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.